Published in Cancer Res on March 10, 2009
The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol (2011) 2.39
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest (2012) 1.92
Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal (2011) 1.50
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell (2016) 1.48
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Rictor regulates cell migration by suppressing RhoGDI2. Oncogene (2012) 1.06
αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell (2013) 0.97
Regulation of Rac1 translocation and activation by membrane domains and their boundaries. J Cell Sci (2014) 0.94
RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells. Oncotarget (2014) 0.93
The Golgi in cell migration: regulation by signal transduction and its implications for cancer cell metastasis. ScientificWorldJournal (2012) 0.90
Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation. J Biol Chem (2012) 0.89
RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases (2011) 0.89
Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat (2010) 0.87
PKCα phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity. Oncogene (2012) 0.86
Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov (2015) 0.84
Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med (Berl) (2013) 0.84
RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res (2014) 0.83
A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget (2015) 0.82
Structural and Mechanistic Insights into the Regulation of the Fundamental Rho Regulator RhoGDIα by Lysine Acetylation. J Biol Chem (2015) 0.81
RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells. Oncol Lett (2012) 0.80
14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget (2013) 0.80
Clinical significance of Rho GDP dissociation inhibitor 2 in colorectal carcinoma. Int J Clin Oncol (2011) 0.78
SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells. Mol Oncol (2013) 0.78
Centrosomal localization of RhoGDIβ and its relevance to mitotic processes in cancer cells. Int J Oncol (2012) 0.77
RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells. Cancer Cell Int (2015) 0.77
Lentivirus vector-mediated Rho guanine nucleotide dissociation inhibitor 2 overexpression induces beta-2 adrenergic receptor desensitization in airway smooth muscle cells. J Thorac Dis (2013) 0.75
Evaluation of dynamic changes in interstitial fluid proteome following microdialysis probe insertion trauma in trapezius muscle of healthy women. Sci Rep (2017) 0.75
Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett (2017) 0.75
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res (1990) 20.53
Rho GTPases and signaling networks. Genes Dev (1997) 11.70
Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol (2001) 5.05
Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell (1998) 5.00
GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol (2005) 4.13
Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science (1997) 3.89
An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med (1999) 3.76
Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI. Nat Cell Biol (2002) 3.50
Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal (1999) 3.00
Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol (1993) 2.71
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
RhoGDI-1 modulation of the activity of monomeric RhoGTPase RhoA regulates endothelial barrier function in mouse lungs. Circ Res (2007) 1.99
In vivo dynamics of Rac-membrane interactions. Mol Biol Cell (2006) 1.95
Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. Oncogene (1994) 1.89
The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat Struct Biol (2000) 1.77
Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res (2004) 1.56
Regulation of morphology by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in Swiss 3T3 cells. J Biol Chem (1993) 1.47
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis (2000) 1.39
RhoGDIs revisited: novel roles in Rho regulation. Traffic (2005) 1.35
Rho activation at a glance. J Cell Sci (2007) 1.29
Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res (2005) 1.21
RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol (2003) 1.17
The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. J Cell Sci (2004) 1.14
Integrin alpha 4 beta 1-dependent T cell migration requires both phosphorylation and dephosphorylation of the alpha 4 cytoplasmic domain to regulate the reversible binding of paxillin. J Biol Chem (2003) 1.10
An activating mutant of Rac1 that fails to interact with Rho GDP-dissociation inhibitor stimulates membrane ruffling in mammalian cells. Biochem J (2004) 0.99
A single residue can modify target-binding affinity and activity of the functional domain of the Rho-subfamily GDP dissociation inhibitors. Proc Natl Acad Sci U S A (1995) 0.98
Defective chemokine-directed lymphocyte migration and development in the absence of Rho guanosine diphosphate-dissociation inhibitors alpha and beta. J Immunol (2006) 0.95
RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol (2007) 0.95
Cell migration: integrating signals from front to back. Science (2003) 29.13
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Measuring mechanical tension across vinculin reveals regulation of focal adhesion dynamics. Nature (2010) 6.25
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Integrins regulate Rac targeting by internalization of membrane domains. Science (2004) 5.07
Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol (2009) 4.58
Mechanisms of mechanotransduction. Dev Cell (2006) 3.95
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Dynamic molecular processes mediate cellular mechanotransduction. Nature (2011) 3.38
Integrin-dependent actomyosin contraction regulates epithelial cell scattering. J Cell Biol (2005) 3.20
Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell Biol (2005) 3.13
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Cancer incidence after localized therapy for prostate cancer. Cancer (2006) 2.52
Cadherin adhesion, tissue tension, and noncanonical Wnt signaling regulate fibronectin matrix organization. Dev Cell (2009) 2.32
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 2.18
Fluid shear stress on endothelial cells modulates mechanical tension across VE-cadherin and PECAM-1. Curr Biol (2013) 2.02
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
Profiling the evolution of human metastatic bladder cancer. Cancer Res (2004) 2.00
In vivo dynamics of Rac-membrane interactions. Mol Biol Cell (2006) 1.95
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol (2003) 1.93
Integrin-mediated adhesion regulates membrane order. J Cell Biol (2006) 1.92
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest (2012) 1.92
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res (2005) 1.89
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer (2002) 1.83
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A (2012) 1.79
Rho mediates the shear-enhancement of endothelial cell migration and traction force generation. Biophys J (2004) 1.77
Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins. Nat Cell Biol (2002) 1.76
Endothelial cell PECAM-1 promotes atherosclerotic lesions in areas of disturbed flow in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2008) 1.76
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69
Matrix-specific suppression of integrin activation in shear stress signaling. Mol Biol Cell (2006) 1.67
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res (2007) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res (2010) 1.54
Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol (2009) 1.53
Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res (2009) 1.44
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol (2005) 1.41
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res (2006) 1.41
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
VE-cadherin links tRNA synthetase cytokine to anti-angiogenic function. J Biol Chem (2004) 1.38
Mechanical stress-activated integrin α5β1 induces opening of connexin 43 hemichannels. Proc Natl Acad Sci U S A (2012) 1.38
Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol (2009) 1.36
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res (2002) 1.31
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther (2007) 1.29
Atheroprone hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation. Circ Res (2010) 1.29
The role of cellular adaptation to mechanical forces in atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.28
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res (2008) 1.28
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res (2011) 1.28
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One (2012) 1.23
Integrins in mechanotransduction. Curr Opin Cell Biol (2013) 1.21
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene (2004) 1.20
Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol (2008) 1.18
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A (2009) 1.17
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17
Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (2008) 1.16
RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling. Curr Biol (2009) 1.16
CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res (2012) 1.16
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol (2007) 1.13
Angiogenesis and prostate cancer tumor growth. J Cell Biochem (2004) 1.13
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci (2012) 1.12
Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem (2006) 1.12
Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res (2003) 1.11
Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett (2003) 1.08
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics (2012) 1.08
Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.08
Lessons from the endothelial junctional mechanosensory complex. F1000 Biol Rep (2012) 1.08
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther (2007) 1.07
Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest (2015) 1.06
Endothelial nuclear factor-κB-dependent regulation of arteriogenesis and branching. Circulation (2012) 1.06
RhoGDI signaling provides targets for cancer therapy. Eur J Cancer (2010) 1.06
Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology (2003) 1.06
Zizimin2: a novel, DOCK180-related Cdc42 guanine nucleotide exchange factor expressed predominantly in lymphocytes. FEBS Lett (2005) 1.05
Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res (2010) 1.05
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther (2009) 1.05
Adrenal tumor with caval extension--case report and review of the literature. Scand J Urol Nephrol (2002) 1.04
Enzymatic properties of rat myelencephalon-specific protease. Biochemistry (2002) 1.03
Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia (2009) 1.03
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem (2002) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Blocking p21-activated kinase reduces lipopolysaccharide-induced acute lung injury by preventing polymorphonuclear leukocyte infiltration. Am J Respir Crit Care Med (2007) 1.01